Phosphoinositide 3-kinase in Health and Disease Volume 1 /

From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in pro...

全面介紹

Saved in:
書目詳細資料
企業作者: SpringerLink (Online service)
其他作者: Rommel, Christian. (Editor, http://id.loc.gov/vocabulary/relators/edt), Vanhaesebroeck, Bart. (Editor, http://id.loc.gov/vocabulary/relators/edt), Vogt, Peter K. (Editor, http://id.loc.gov/vocabulary/relators/edt)
格式: 電子 電子書
語言:English
出版: Berlin, Heidelberg : Springer Berlin Heidelberg : Imprint: Springer, 2011.
版:1st ed. 2011.
叢編:Current Topics in Microbiology and Immunology, 346
主題:
在線閱讀:https://doi.org/10.1007/978-3-642-13663-4
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!
書本目錄:
  • PI3K – From the Bench to the Clinic and Back
  • PI3K Book Introduction
  • PDK1: The major transducer of PI 3-Kinase actions
  • Protein Kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway
  • Regulatory subunits of class IA PI3K
  • The Regulation of Class IA PI 3-kinases by Inter-Subunit Interactions
  • Phosphoinositide signalling pathways in metabolic regulation
  • Role of RAS in the regulation of PI 3-kinase
  • More than just kinases: The scaffolding function of PI3K
  • PI3K signalling in neutrophils
  • PI 3-kinase p110beta regulation of platelet integrin alphaIIbbeta3
  • PI3Ks in lymphocyte signalling and development
  • PI3 kinase regulation of skeletal muscle hypertrophy and atrophy
  • Taking PI3Kdelta and PI3Kgamma one step ahead – Dual active PI3Kdelta/gamma inhibitors for the treatment of immune-mediated inflammatory diseases
  • Oncogenic Mutations of PIK3CA in Human Cancers
  • Structural Effects of Oncogenic PI3Kalpha Mutations
  • Comparing the roles of the p110alpha and p110beta isoforms of PI3K in signaling and cancer
  • Phosphatidylinositol 3-kinase (PI3K): The oncoprotein
  • AKT Signaling in Physiology and Disease
  • Faithfull modeling of PTEN loss driven diseases in the mouse
  • PI3K as a target for therapy in haematological malignancies
  • Clinical development of Phosphatidylinositol-3 kinase pathway inhibitors
  • New inhibitors of the PI3K-Akt-mTOR pathway: Insights into mTOR signaling from a new generation of Tor kinase domain inhibitors (TORKinibs)
  • Small molecule inhibitors of the PI3-kinase family
  • Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance
  • Subject index.